BACKGROUND: Epidemiological studies from the last decade have suggested that the morbidity and mortality associated with a newly emergent strain of human adenovirus (HAdV-14p1) is greater than other, more prevalent, adenovirus strains. Recent molecular analysis identified very minor genetic differences in HAdV-14p1 compared to prototype HAdV-14p. No studies have evaluated how these differences may affect virulence. OBJECTIVE: To compare HAdV-14p1 and HAdV-14p strains for competitive fitness and virulence. STUDY DESIGN: We performed in vitro and molecular assays to evaluate growth kinetics, cellular infectivity, cytotoxicity, and plaque morphology of the two strains. RESULTS: Growth kinetic data showed no viral replication at 30°C and minimal differences at 37°C for both strains. Cellular infectivity data showed propagation capabilities for both strains in a diverse array of cell lines, with human lung and kidney cells having the highest propagation potential. Cytotoxicity data indicated cellular distress differences induced by both strains of virus in the first 12h, but similar distress levels between 12 and 48 h. Plaque morphology assays showed some differences in average plaque diameter. CONCLUSIONS: These data suggest that the increase in morbidity and mortality observed in recent HAdV-14p1 infections is not due to viral growth or cellular infectivity differences from the prototypic HAdV-14 strain. While there were some statistically important differences detected between strains in cytotoxicity and plaque morphology assays, it seems more likely that other factors, such as environmental stressors, co-infections, or individual host response are likely contributing to the increase in morbidity.
BACKGROUND: Epidemiological studies from the last decade have suggested that the morbidity and mortality associated with a newly emergent strain of human adenovirus (HAdV-14p1) is greater than other, more prevalent, adenovirus strains. Recent molecular analysis identified very minor genetic differences in HAdV-14p1 compared to prototype HAdV-14p. No studies have evaluated how these differences may affect virulence. OBJECTIVE: To compare HAdV-14p1 and HAdV-14p strains for competitive fitness and virulence. STUDY DESIGN: We performed in vitro and molecular assays to evaluate growth kinetics, cellular infectivity, cytotoxicity, and plaque morphology of the two strains. RESULTS: Growth kinetic data showed no viral replication at 30°C and minimal differences at 37°C for both strains. Cellular infectivity data showed propagation capabilities for both strains in a diverse array of cell lines, with human lung and kidney cells having the highest propagation potential. Cytotoxicity data indicated cellular distress differences induced by both strains of virus in the first 12h, but similar distress levels between 12 and 48 h. Plaque morphology assays showed some differences in average plaque diameter. CONCLUSIONS: These data suggest that the increase in morbidity and mortality observed in recent HAdV-14p1 infections is not due to viral growth or cellular infectivity differences from the prototypic HAdV-14 strain. While there were some statistically important differences detected between strains in cytotoxicity and plaque morphology assays, it seems more likely that other factors, such as environmental stressors, co-infections, or individual host response are likely contributing to the increase in morbidity.
Authors: Jacqueline E Tate; Michel L Bunning; Lisa Lott; Xiaoyan Lu; John Su; David Metzgar; Lorie Brosch; Catherine A Panozzo; Vincent C Marconi; Dennis J Faix; Mila Prill; Brian Johnson; Dean D Erdman; Vincent Fonseca; Larry J Anderson; Marc-Alain Widdowson Journal: J Infect Dis Date: 2009-05-15 Impact factor: 5.226
Authors: Paul F Lewis; Mark A Schmidt; Xiaoyan Lu; Dean D Erdman; Mary Campbell; Ann Thomas; Paul R Cieslak; La Donna Grenz; Laura Tsaknardis; Curt Gleaves; Brian Kendall; David Gilbert Journal: J Infect Dis Date: 2009-05-15 Impact factor: 5.226
Authors: Fernanda C Lessa; Philip L Gould; Neil Pascoe; Dean D Erdman; Xiaoyan Lu; Michel L Bunning; Vincent C Marconi; Lisa Lott; Marc-Alain Widdowson; Larry J Anderson; Arjun Srinivasan Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Janice K Louie; Adriana E Kajon; Mark Holodniy; Lilly Guardia-LaBar; Brian Lee; Ann M Petru; Jill K Hacker; David P Schnurr Journal: Clin Infect Dis Date: 2008-02-01 Impact factor: 9.079
Authors: Morris Saffold Jones; Balázs Harrach; Robert D Ganac; Mary M A Gozum; Wilfred P Dela Cruz; Brian Riedel; Chao Pan; Eric L Delwart; David P Schnurr Journal: J Virol Date: 2007-03-14 Impact factor: 5.103
Authors: G P Buzatto; E Tamashiro; J L Proenca-Modena; T H Saturno; M C Prates; T B Gagliardi; L R Carenzi; E T Massuda; M A Hyppolito; F C P Valera; E Arruda; W T Anselmo-Lima Journal: PLoS One Date: 2017-02-23 Impact factor: 3.240